Gimatecan
An investigational anticancer drug
Gimatecan is a synthetic camptothecin derivative that is being investigated for its potential use as an anticancer agent. It belongs to the class of topoisomerase inhibitors, specifically targeting topoisomerase I, an enzyme crucial for DNA replication and transcription.
Mechanism of Action[edit | edit source]
Gimatecan exerts its anticancer effects by inhibiting the activity of topoisomerase I. This enzyme is responsible for relieving torsional strain in DNA by inducing reversible single-strand breaks. Gimatecan stabilizes the complex formed between topoisomerase I and DNA, preventing the re-ligation of the DNA strand and ultimately leading to double-strand breaks. These breaks can trigger apoptosis in rapidly dividing cancer cells.
Pharmacokinetics[edit | edit source]
Gimatecan is administered orally and has shown favorable pharmacokinetic properties in preclinical studies. It is characterized by good oral bioavailability and a long half-life, which may allow for less frequent dosing compared to other topoisomerase I inhibitors.
Clinical Trials[edit | edit source]
Gimatecan has been evaluated in several clinical trials for its efficacy and safety in treating various types of cancer, including lung cancer, breast cancer, and ovarian cancer. Early-phase trials have demonstrated promising antitumor activity and a manageable safety profile. However, further studies are needed to fully establish its clinical utility.
Side Effects[edit | edit source]
As with other topoisomerase I inhibitors, gimatecan can cause a range of side effects. Common adverse effects include myelosuppression, nausea, vomiting, and diarrhea. The severity of these side effects can vary depending on the dose and schedule of administration.
Research and Development[edit | edit source]
Gimatecan is still under investigation, and ongoing research aims to optimize its therapeutic potential. Studies are exploring its use in combination with other anticancer agents and its effectiveness in different cancer subtypes. Researchers are also investigating biomarkers that may predict response to gimatecan therapy.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
